Supplementary Table 1. Summary of clinical trials of BiTE/BiAb (Out of pipeline).

Agents (target)	Trial and participant data	Protocol	Efficacy	Safety
Pacanalotamab (AMG 420, BI 836909) BCMA x CD3	1. Phase 1 trial (NCT02514239) 2. RRMM, n= 42 3. Median age: 65 (range: 39-79). 4. Prior lines of Tx: 5 5. HR cytogenetics: 33% 6. Prior daratumumab: 29% 7. Prior elotuzumab: 10% 8. Prior auto-HSCT: 86%	1. Dose escalation study. 2. Six-week cycles of AMG 420 up to 10 cycles (4 weeks continuous IV infusion + 2 weeks off). 3. Single-patient cohorts [0.2–1.6 µg/day (d)] followed by cohorts of 3–6 patients (3.2–800 µg/d).	1. ORR: 31% (13/42). 2. Responses (+) at 6.5 µg/d. 3. Median time to response: 1.4 months. 4. ORR at 400 µg/d: 70% (7/10), including 5 MRD-negative CRs, 1 VGPR, and 1 PR.	1. SAE: 20 (48%), including infection (n= 14) and polyneuropathy (n= 2). 2. CRS: 16, including 2 Gr 2 and 1 Gr 3. 3. No Gr≥ 3 CNS toxicities. 4. DLT (+): 2 patients (2/3, at 800µg/d)
Pavurutamab (AMG 701) BCMA x CD3	1. Phase 1 (NCT03287908) 2. RRMM, n= 75 3. Median age: 63 years 4. Prior lines of Tx: 6 (1-25) 5. EMD: 27% 6. Prior HSCT: 83% 7. Prior anti-CD38 MoAb: 93% 8. Triple refractory: 68%	1. AMG 701 IV infusions: weekly in 4-week cycles until PD. 2. Target doses (mg): 0.14, 0.4, 0.8, 1.2, 1.6. 3.0, 4.5, 6.5, 9, 12.	1. ORR: 36% (16/45) at doses of 3-12 mg. 2. ORR: 83% (5/6, 3 PRs, 2 VGPRs) (earlier dose escalation with 9 mg). 3. Median time to response: 1.0 month. 4. MRD in 4 CR patients: all negative (4/4).	1. Hematological AEs: anemia (43%), neutropenia (23%), and thrombocytopenia (20%). 2. Non-hematological AEs: CRS (61%), diarrhea (31%), fatigue (25%), and fever (25%). 3. All Gr 3 CRS (n= 5, 7%) were assessed as DLTs. 4. SAE (n= 29, 39%): infections (n= 13), CRS (n= 7), and asymptomatic pancreatic enzyme rise (n= 2). 5. Neurotoxicity: 6 (4 CRS-related, all Gr 1/2)

AE, adverse event; CNS, central nervous system; CR, complete remission; CRS, cytokine releasing syndrome; DLT, dose-limiting toxicity; EMD, extramedullary disease; Gr, grade; HR, high-risk; HSCT, hematopoietic stem cell transplantation; IV, intravenous; MoAb, monoclonal antibody; MRD, minimal residual disease; ORR, overall (objective) response rate; PR, partial response; SAE, serious AE; Tx, treatment; VGPR, very good partial response.